Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PCV13 in Preterm vs Term Infants
NCT01193335Phase 4Completed
- Sponsor
- Pfizer
- Start
- Oct 2010
- Primary completion
- Jan 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 4, open-label trial of Prevnar 13 in pneumococcal infection (2 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=) 0.35 Microgram Per Milliliter (mcg/mL), Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody and 3 more. Started Oct 2010; status: completed.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT01193335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01193335.